DIAGNOS initiates a clinical trial study in the USA for early detection and prevention of Stroke using its new application CA...
July 20 2021 - 10:05AM
Diagnos Inc. (“
DIAGNOS” or the
“
Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a
leader in early detection of critical health issues, announces
today the initiation of a clinical trial study with CommonSpirit
Health Research Institute, Chattanooga Center for Neurologic
Research LLC and conducted at the CommonSpirit Hospital in
Chattanooga, to confirm early Proof-of-Concept results that showed
a strong potential in the early detection of stroke through the
inspection and analysis of the retina.
The clinical trial will be carried out under the
direction of Thomas G Devlin M.D., PhD. The IRB study has been
approved by an Institutional Review Board (“IRB”) in compliance
with all applicable regulations in the USA.
“DIAGNOS will be providing the necessary
hardware and technical support during the first phase of the
clinical trial. DIAGNOS will have access to all the results tests
performed on patients who are admitted to the hospital following a
stroke and who meet the study’s inclusion criteria. The tests
performed on these patients will include taking images of the
retina using DIAGNOS’ CARA-ST technology. The analysis of the
retina by our AI application will be done immediately and all
medical staff in the clinical trial will have access to it through
our FDA-approved Tele-Medicine platform. The initial goal of the
first phase of the study is to demonstrate that the results using
CARA-ST correlate with the results of the other clinical results.
If successful, the second phase would start shortly thereafter and
will be screening over 1,000 patients at the same facility and also
a new facility in Canada.
DIAGNOS is seeking to demonstrate that CARA-ST
will be able to predict the early signs of the condition leading to
stroke, based on the micro circulation analysis of the retina image
of the patient.
As per CDC-The Center for Disease Control and
Prevention, stroke causes 1 out of every 20 deaths, the management
of stroke represents a cost of around USD 34
billion per year in the United States. Hence, early
diagnosis and treatment to prevent deaths from stroke is a time
sensitive necessity.
According to the World Health Organization, 15
million people suffer a stroke
worldwide each year. Of these, 5 million die and
another 5 million are permanently disabled. High blood pressure
contributes to more than 85% of strokes
worldwide. Europe averages
approximately 650,000 stroke related
deaths each year.
“According to new reports published by Worldwide
Research Institutes, the worldwide market size for Stroke
Management will hit over $66 Billion dollars by 2023. DIAGNOS
intends to be part of the solution by making available an
affordable predictive test to the general public’’ said Mr. André
Larente, President of DIAGNOS.
“At DIAGNOS we have continued to invest in
Research and Development, furthering the creation of our
intellectual property by partnering with Quebec government programs
and local university (École de Technologie Supérieure) to ensure we
stay ahead of our competition worldwide. This year our new stroke
management application will be field tested in multiple countries.
For our investors this ground-breaking test comes at an ideal time
in terms of shareholder value creation as the combination of both
CARA-DR and CARA-ST tools will be transformational in helping to
monitor the health of existing and future patients with
cardiovascular disease,” said Mr. Andre Larente, President
of DIAGNOS.
About CommonSpirit CommonSpirit
Health is a non for profit, Catholic health system dedicated to
advancing health for all people. It was created in February 2019
through the alignment of Catholic Health initiatives and Dignity
Health. With a team of approximately 125,000 physicians and
advanced practice clinicians. CommonSpirit Health operates 137
hospitals and more than 1,000 care sites across 21 states. In
FY2020, Catholic Health initiatives and Dignity Health had combined
revenues of nearly $29.6 billion and provided $4.6 billion in
charity care, community benefit and unreimbursed government
programs.
About DIAGNOS DIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President DIAGNOS Inc. Tel:
450-678-8882 ext. 224 alarente@diagnos.ca
Corporate Communications: Nancy Massicotte IR
Pro Communications Inc. Dir: +1 604-507-3377 TF: 1-866-503-3377
Email: nancy@irprocommunications.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Sep 2023 to Sep 2024